PDCD1 and non-small cell lung carcinoma: The US Food and Drug Administration (FDA) has approved two PD-1-targeted MAbs, nivolumab from Bristol-Myers Squibb (Opdivo, also known as BMS-936558, MDX-1106, and ONO-4538) and pembrolizumab from Merck (Keytruda, also known as lambrolizumab and MK-3475), for advanced melanoma, non-small cell lung cancer (NSCLC), and kidney cancer.